Bernd Kasper, ESMO 2022: DeFi phase 3 trial investigating nirogacestat versus placebo for progressing desmoid tumors
Desmoid tumours are rare, locally aggressive soft-tissue tumours that are challenging to manage, due to lack of approved therapies, and variable presentation. Dr Bernd Kasper (Universitätsmedizin Mannheim, Mannheim, Germany) joins touchONCOLOGY to discuss the phase 3 DeFi study, a global randomized, double-blind, placebo-controlled trial in adults with progressing desmoid tumours. The trial investigates nirogacestat, a novel oral gamma secretase inhibitor, that has shown antitumour activity in patients with desmoid tumours.
The abstract entitled ‘DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors‘ Abstract LBA2, was presented at European Society for Medical Oncology (ESMO) 2022.
Questions:
- Could you tell us a little about desmoid tumours and the unmet needs in their treatment? (0:19)
- What is nirogacestat and what is the rationale for its use in the treatment of desmoid tumours? (1:13)
- What were the aims, design and eligibility criteria of the DeFi study? (1:52)
- What were the efficacy and safety findings of the study? (2:40)
Disclosures: Bernd Kasper is a consultant for and receives grant/research support from Springworks;Â is on the advisory board for Bayer, Blueprint, Boehringer Ingelheim, Springworks, GSK, PharmaMar, and Ayala; invited Speaker for PharmaMar, Springworks, Ayala.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
